Trial Profile
A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Vistusertib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Proof of concept
- Sponsors Acerta Pharma
- 01 Nov 2021 Results published in the Leukemia and Lymphoma
- 04 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 12 Mar 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.